{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:28:46Z","timestamp":1789241326401,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T34 GM008074"],"award-info":[{"award-number":["T34 GM008074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM099594"],"award-info":[{"award-number":["GM099594"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008090","name":"Tufts University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.colsurfb.2023.113326","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:06:53Z","timestamp":1682334413000},"page":"113326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Hybrid peptides as platform for synchronized combination therapy"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8695-6649","authenticated-orcid":false,"given":"Elahe","family":"Ashrafichoobdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-4212","authenticated-orcid":false,"given":"Tanner","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luladey","family":"Ayalew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus","family":"Gorbanwand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-2918","authenticated-orcid":false,"given":"Katarzyna","family":"Slowinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2023.113326_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","article-title":"Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy","volume":"20","author":"Ismail","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.colsurfb.2023.113326_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.colsurfb.2023.113326_bib3","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.colsurfb.2023.113326_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.colsurfb.2023.113326_bib5","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharm."},{"key":"10.1016\/j.colsurfb.2023.113326_bib6","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1021\/nn405674m","article-title":"Nanoparticles for combination drug therapy","volume":"11","author":"Ma","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2023.113326_bib7","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1039\/C5MD00365B","article-title":"Multi-drug delivery nanocarriers for combination therapy","volume":"6","author":"Gadde","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.colsurfb.2023.113326_bib8","first-page":"43","article-title":"Current methods for quantifying drug synergism","volume":"1","author":"Ma","year":"2019","journal-title":"Prote Bioinform"},{"key":"10.1016\/j.colsurfb.2023.113326_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/fon-2017-0607","article-title":"Improving combination cancer therapy: the CombiPlex development platform","volume":"14","author":"Tolcher","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.colsurfb.2023.113326_bib10","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-020-16735-2","article-title":"A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities","volume":"11","author":"Narayan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2023.113326_bib11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/DDDT.S198056","article-title":"Combination of drugs and carriers in drug delivery technology and its development","volume":"13","author":"Du","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.colsurfb.2023.113326_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.colsurfb.2023.113326_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121863","article-title":"Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview","volume":"623","author":"Javia","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113326_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cocis.2017.08.002","article-title":"A review on engineering polymer drug conjugates to improve combination chemotherapy","volume":"31","author":"Vogusa","year":"2017","journal-title":"Curr. Opp. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2023.113326_bib15","doi-asserted-by":"crossref","first-page":"17345","DOI":"10.1038\/s41598-018-35559-1","article-title":"A biophysical study on the mechanism of interactions of DOX or PTX with \u03b1-lactalbumin as a delivery carrier","volume":"8","author":"Delavari","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2023.113326_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.colsurfb.2023.113326_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/anie.201608292","article-title":"Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates","volume":"56","author":"Levengood","year":"2017","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.colsurfb.2023.113326_bib18","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1039\/C4CS00139G","article-title":"\u201cClick\u201d reactions: a versatile toolbox for the synthesis of peptide-conjugates","volume":"43","author":"Tang","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.colsurfb.2023.113326_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2014.05.025","article-title":"Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs","volume":"187","author":"Markovsky","year":"2014","journal-title":"J. Control Release"},{"key":"10.1016\/j.colsurfb.2023.113326_bib20","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1021\/ja0683640","article-title":"Self-assembled heterotrimeric collagen triple helices directed through electrostatic interactions","volume":"129","author":"Gauba","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.colsurfb.2023.113326_bib21","doi-asserted-by":"crossref","first-page":"15034","DOI":"10.1021\/ja075854z","article-title":"Surprisingly high stability of collagen abc heterotrimer: evaluation of side chain charge pairs","volume":"129","author":"Gauba","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.colsurfb.2023.113326_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/ja209669u","article-title":"Rational design of single-composition ABC collagen heterotrimers","volume":"134","author":"Fallas","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.colsurfb.2023.113326_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jsb.2013.04.006","article-title":"Design of net- charged Abc-type collagen heterotrimers","volume":"185","author":"Parmar","year":"2014","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.colsurfb.2023.113326_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1020566218512","article-title":"A Phase I. Toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer","volume":"76","author":"Emens","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.colsurfb.2023.113326_bib25","doi-asserted-by":"crossref","first-page":"R681","DOI":"10.1186\/bcr1274","article-title":"Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines","volume":"7","author":"Zoli","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.colsurfb.2023.113326_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/pharmaceutics9030035","article-title":"Pharmacokinetic and toxicodynamic characterization of a novel doxorubicin derivative","volume":"9","author":"Alrushaid","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2023.113326_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12935-018-0625-9","article-title":"Sulbactam\u2011enhanced cytotoxicity of doxorubicin in breast cancer cells","volume":"18","author":"Wen","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.colsurfb.2023.113326_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorna","year":"2011","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.colsurfb.2023.113326_bib29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracyl: mechanism of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev."},{"key":"10.1016\/j.colsurfb.2023.113326_bib30","doi-asserted-by":"crossref","first-page":"15777","DOI":"10.1021\/acsomega.9b03574","article-title":"Potential anti-tumor drug: co-crystal 5-fluorouracil-nicotinamide","volume":"5","author":"Zhang","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.colsurfb.2023.113326_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11094-021-02526-6","article-title":"Determination of Paclitaxel solubility and stability in the presence of injectable excipient","volume":"55","author":"Sadeghi-Oroumiyeh","year":"2021","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.colsurfb.2023.113326_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the management of ovarian cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.colsurfb.2023.113326_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1248\/bpb.31.103","article-title":"Synthesis of poly(vinyl alcohol)\u2013doxorubicin conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release","volume":"31","author":"Kakinoki","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.colsurfb.2023.113326_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/app.39247","article-title":"Improved stability and tumor targeting of 5-fluorouracil by conjugation with hyaluronan","volume":"130","author":"Dong","year":"2013","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.colsurfb.2023.113326_bib35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/jm00124a011","article-title":"Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity","volume":"32","author":"Deutsch","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2023.113326_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/psc.2725","article-title":"Peptide internalization enabled by folding: triple helical cell-penetrating peptides","volume":"21","author":"Shinde","year":"2015","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.colsurfb.2023.113326_bib37","doi-asserted-by":"crossref","first-page":"9654","DOI":"10.1021\/acs.analchem.6b02438","article-title":"Thermoresponsive collagen\/cell penetrating hybrid peptide as nanocarrier in targeting-free cell selection and uptake","volume":"88","author":"Oh","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.colsurfb.2023.113326_bib38","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1021\/bi001560d","article-title":"Amino acid propensities for the collagen triple-helix","volume":"39","author":"Persikov","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.colsurfb.2023.113326_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/acsmedchemlett.7b00117","article-title":"Conjugation of paclitaxel to hybrid peptide carrier and biological evaluation in Jurkat and A549 cancer cell lines","volume":"8","author":"Ayalew","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.colsurfb.2023.113326_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113326_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235929","article-title":"Guided screen for synergistic three-drug combinations","volume":"15","author":"Cokol-Cakmak","year":"2020","journal-title":"PLoS ONE"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776523002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776523002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:19:32Z","timestamp":1760527172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776523002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"alternative-id":["S0927776523002047"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113326","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid peptides as platform for synchronized combination therapy","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113326"}}